Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Express Scripts
Fish and Richardson
Mallinckrodt
US Department of Justice
McKesson
Novartis
Healthtrust
Harvard Business School
US Army

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,691,878 protect, and when does it expire?


Patent ► Subscribe protects KALETRA and NORVIR and is included in two NDAs. There have been zero Paragraph IV challenges on Kaletra and Norvir

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: ► Subscribe

Title:Solid pharmaceutical dosage form
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Inventor(s): Rosenberg; Jeorg (Ellerstadt, DE), Reinhold; Ulrich (Heidelberg, DE), Liepold; Bernd (Dossenheim, DE), Berndl; Gunther (Herxheim, DE), Breitenbach; Joerg (Mannheim, DE), Alani; Laman (Foster City, CA), Ghosh; Soumojeet (Lansdale, PA)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/674,799
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► SubscribeY
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► SubscribeY
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Queensland Health
Colorcon
Federal Trade Commission
Moodys
Argus Health
Daiichi Sankyo
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot